Melanoma antigens are biomarkers for ipilimumab response

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 2, 2017, Pages 252-259

  Arenberger, P ^a   Fialova, A ^a   Gkalpakiotis, S ^a   Pavlikova, A ^a   Puzanov, I ^b   Arenbergerova, M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 100; IPILIMUMAB; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MELANOMA INHIBITORY ANTIGEN; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MELANOMA CELL; METASTATIC MELANOMA; MIDDLE AGED; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SURVIVAL TIME; TREATMENT RESPONSE; BLOOD; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 85010644702     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13940     Document Type: Article

References (23)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.
2. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517–2526.
3. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013; 19: 1009–1020.
4. Miyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells-monitoring treatment response in prostate cancer. Nat Rev Clin Oncol 2014; 11: 401–412.
5. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781–791.
6. Nezos A, Lembessis P, Sourla A et al. Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. Clin Chem Lab 2009; 47: 1–11.
7. Klinac D, Gray ES, Freeman JB et al. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer 2014; 14: 423–429.
8. Khoja L, Lorigan P, Zhou C et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol 2013; 133: 1582–1590.
9. Klinac D, Gray ES, Millward M et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013; 3: 54.
10. Arenberger P, Arenbergerova M, Gkalpakiotis S et al. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method. J Eur Acad Dermatol Venereol 2008; 22: 56–64.
11. Gkalpakiotis S, Arenberger P, Kremen J et al. Quantitative detection of melanoma-associated antigens by multimarker real-time RT-PCR for molecular staging: results of a 5 years study. Exp Dermatol 2010; 19: 994–999.
12. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412–7420.
13. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199–6206.
14. Wilgenhof S, Du Four S, Vandenbroucke F et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013; 36: 215–222.
15. Ku GY, Yuan J, Page DB et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116: 1767–1775.
16. Berrocal A, Arance A, Lopez Martin JA et al. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Melanoma Res 2014; 24: 577–583.
17. Koyanagi K, Kuo C, Nakagawa T et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. ClinChem 2005; 51: 981–988.
18. Kiyohara E, Hata K, Lam S, Hoon DS. Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients. Methods Mol Biol 2014; 1102: 513–522.
19. Reid AL, Millward M, Pearce R et al. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol 2013; 168: 85–92.
20. Freeman JB, Gray ES, Millward M et al. Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med 2012; 10: 192.
21. Luo X, Mitra D, Sullivan RJ et al. Isolation and molecular characterization of circulating melanoma cells. Cell Rep 2014; 7: 645–653.
22. Vétizou M, Pitt JM, Daillère R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350: 1079–1084.
23. Martens A, Wistuba-Hamprecht K, Geukes Foppen MH et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 2016; 22: 2908–2918.